Protagenic Therapeutics (PTIX) said Wednesday that warrant exchanges and exercises in the past four business days yielded $3.1 million in cash.
The proceeds will be used to fund working capital and advance Protagenic's peptide-based drug candidates for stress and central-nervous-system disorders, according to a statement.
Meanwhile, the company said it executed a business combination with Phytanix Bio, integrating six programs under one company.
Price: 6.91, Change: +0.03, Percent Change: +0.39
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.